###### Strengths and limitations of this study

-   This study is the first to report sex disparities in cause-specific premature adult mortality in Estonia with an emphasis on alcohol-related and smoking-related causes of death.

-   Special attention paid to cause-specific men-to-women mortality rate ratios helped to reveal different health behaviour among men and women.

-   Individual death records from the population-based mortality register were used.

-   The exclusion of deaths records with an unknown date of birth (more common among men) slightly reduced the men-to-women mortality rate ratios.

-   Heavy alcohol consumption has likely been underestimated in the Estonian health behaviour survey.

Introduction {#s1}
============

Estonia is a high-income country in northern Europe with an area of 45 230 km^2^ and a population of 1.3 million. According to data from 2017, the country's gross domestic product per capita (2011 PPP \$) was 29 481 (40th globally). Estonia belongs to the group of countries with a very high human development index (30th globally) and a very high gender inequality index (27th globally).[@R1] Among the 28 European Union member countries (EU-28), Estonia ranks third with the largest sex gap in life expectancy at birth.[@R2] Over the decade of 1976--1985, life expectancy at birth in Soviet Estonia remained almost unchanged, fluctuating between 64 and 65 years for men and between 74 and 75 years for women ([figure 1](#F1){ref-type="fig"}).[@R3] Gorbachev's antialcohol campaign, launched in 1985,[@R4] triggered a remarkable short-term improvement in male life expectancy---from 64.6 in 1985 to 66.6 in 1988. The positive trend was followed by a sharp decrease during the dissolution of the Soviet Union and the first years of Estonian reindependence in 1991--1994 because of worsening of macroeconomic conditions and related fall in living standards, which coincided with weakening of alcohol restrictions.[@R5] Life expectancy for men and women dropped to the lowest level in 1994, 60.5 and 72.8 years, respectively. From 1995 onwards, life expectancy has increased markedly, reaching 73.2 years for men and 81.9 years for women in 2016[@R3] (compared with the EU-28 average of 78.2 and 83.6, respectively[@R6]); however, the male disadvantage of 9--10 years has remained unchanged. The lowest difference of 8.4 years was observed in 1988, but in 2016, the difference still stands at 8.7 years. Although women outlive men all over the world,[@R7] only 1--2 years of the sex gap can be explained by biological factors.[@R8]

![Life expectancy at birth, Estonia, 1976--2016.[@R3]](bmjopen-2018-026210f01){#F1}

The objective of the present study was to quantify relative sex disparities in cause-specific premature adult mortality in Estonia over time. We wanted to determine for which causes of death the inequalities were the largest, providing insight into related behaviours that differ the most between Estonian men and women. Finally, we aimed to offer some guidance to public health policy-makers based on the results of the study.

Methods {#s2}
=======

Data {#s2a}
----

Individual death data in 1995--2016 were obtained from the Estonian causes of death register including single records since 1983.[@R9] Premature adult deaths were defined as those occurring between the ages of 20 and 69 years, setting the upper limit close to the life expectancy for men. We have chosen 1995 as the start year for three reasons: (1) A steady decline in mortality started in this year[@R10]; (2) A year earlier, a less detailed Soviet classification was replaced with the genuine international classification of diseases (ICD)[@R11] for coding causes of death (ICD-9 in 1994--1996 and ICD-10 in 1997--2016)[@R13] and (3) The victims of the Estonia ferry accident in 1994[@R14] (120 men and 137 women aged 20--69 years) were thus left out from the analysis. Only underlying causes of death were considered.

In addition, data on smoking and drinking habits in the population aged 20--64 years were obtained from the biennial postal survey of health behaviour of Estonian adult population (the Finbalt survey).[@R15]

Measures and statistical analyses {#s2b}
---------------------------------

For mortality comparisons, we first calculated the overall and cause-specific age-standardised mortality rates (ASMR; European standard population[@R16]) for the years 1995--2016 for men and women aged 20--69 years. Time trends are presented for overall mortality and for major groups of causes of death: infectious diseases, neoplasms, circulatory diseases, respiratory diseases, digestive diseases and external causes of death. To reduce short-term fluctuations in mortality rates by year, 3-year moving, overlapping periods were used. In addition, time trends for mortality from lung cancer, chronic obstructive pulmonary disease (COPD), cancer of the upper aerodigestive tract (UADT), liver cirrhosis and from a group of mental disorders due to alcohol, alcohol-related degeneration of the nervous system and alcohol poisoning (hereafter AP) are shown. Mortality from these causes is highly sensitive to changes in the prevalence of tobacco smoking and/or alcohol consumption in the population.[@R17] AP grouping was performed because of systematic misclassification of these causes in the mortality register,[@R9] and the effect of which should be captured by treating these individual causes together. Average annual percentage changes (AAPC) with 95% confidence intervals (CI) for ASMRs in 1995--2016 were modelled with Poisson regression. For selected alcohol-related causes, the study period was split into two subperiods both including 2007 when alcohol consumption in the country was at its maximum.[@R22]

Second, Poisson regression was used to estimate cause-specific men-to-women mortality rate ratios (MRRs) with 95% CI for the period 1995--2016 and the age range of 20--69. The models were adjusted for age (5-year age groups) and year of death. For selected causes of death, MRRs were also calculated separately for the younger (20--44 years) and older (45--69 years) age groups. Poisson regression models were fitted to the annual MRRs to obtain AAPCs.

Third, age-standardised prevalence proportions (ASPP; European standard population) in 1996--2016 for men and women were calculated for daily smoking, heavy episodic drinking (≥60 g of pure alcohol per occasion at least once a week) and hazardous drinking (≥210 g and ≥140 g of pure alcohol weekly for men and women, respectively). Heavy episodic drinking and hazardous drinking were defined as recommended by the Organization for Economic Co-operation and Development.[@R23] Men-to-women prevalence proportion ratios (PPRs) with 95% CIs were calculated using Poisson regression models adjusted for age (5-year age groups) and survey year.

FoxPro 9.0 (Microsoft Corporation, Redmond, WA, USA) was used for database management and Stata 14 (StataCorp LP, College Station, TX, USA) for statistical modelling.

Patient and public involvement {#s2c}
------------------------------

Patients or public were not involved in this study.

Results {#s3}
=======

In the period 1995--2016, 191 123 deaths were registered among men and 189 390 deaths among women in Estonia. The crude male mortality rate (per 100 000) was 1626.3 in 1995 and 1181.6 in 2016, and the crude female mortality rates were 1296.2 and 1143.3, respectively. The corresponding age-standardised male mortality rates were 1896.6 and 977.8, and the female mortality rates were 895.5 and 475.8. Age was missing for 1178 male deaths and for 207 female deaths; for both sexes, 49% of these deaths were due to external causes, and for 27% the underlying cause of death was unknown. More than half of the male deaths (102 497) and nearly a quarter of the female deaths (44 080) were classified as premature adult deaths (age 20--69 years) in the current study. Of these, external causes accounted for 23.7% of the male deaths and 12.2% of the female deaths; the underlying cause of death was unknown for 2.4% and 1.2% of premature deaths, respectively.

Over the 22 years of the study, there was a roughly twofold decrease in the overall mortality for both men and women: the ASMR per 100 000 dropped from 1651.5 to 716.3 and from 530.0 to 255.2, respectively. Mortality in men exceeded that in women by a factor of three, and the relative sex difference remained stable over the study period ([table 1](#T1){ref-type="table"}, online [supplementary figure S1](#SP1){ref-type="supplementary-material"}). All major groups of causes of death, except digestive diseases, demonstrated a steady downward trend for both sexes; a male disadvantage was obvious for all groups of causes of death ([figure 2](#F2){ref-type="fig"}).
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![Three-year moving age-standardised mortality rates (European standard population) by major groups of death causes, age 20--69 years, Estonia, 1995--2016.](bmjopen-2018-026210f02){#F2}

###### 

Mortality characteristics, age 20--69 years, Estonia, 1995--2016

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ICD-10                              Cause of death                           Men, ASMR   Women, ASMR   Men-to-women MRR\       AAPC of MRR\                                                          
                                                                                                         (95% CI)                (95% CI)                                                              
  ----------------------------------- ---------------------------------------- ----------- ------------- ----------------------- -------------- ------- ---------------------- ----------------------- ----------------------
  A00--Y98                            All causes                               1651.5      716.3         −3.7 (−4.0 to −3.4)     530.0          255.2   −3.7 (−3.9 to −3.4)    2.96 (2.93 to 3.00)     0.0 (−0.2 to 0.2)

  A00--B99                            Infectious diseases                      32.3        12.9          −3.9 (−4.5 to −3.3)     5.3            5.7     0.3 (−1.0 to 1.6)      4.06 (3.69 to 4.47)     −4.5 (−6.0 to −3.0)

  A15--A19                             Tuberculosis                            26.2        2.7           −11.1 (−12.5 to −9.7)   3.3            0.3     −9.8 (−12.6 to −7.0)   6.49 (5.61 to 7.53)     0.1 (−2.4 to 2.6)

  B20--B24                             HIV disease\*                           NA          5.4           −0.5 (−5.4 to 4.5)      NA             4.3     2.5 (−2.7 to 7.6)      2.85 (2.32 to 3.50)     −1.6 (−9.5 to 6.2)

  C00--D48                            Neoplasms                                292.0       184.5         −2.1 (−2.3 to −1.9)     138.3          109.1   −1.7 (−1.9 to −1.4)    1.94 (1.90 to 1.98)     −0.4 (−0.7 to −0.0)

  C01--C15, C32                        UADT                                    31.5        23.8          −1.5 (−2.1 to −0.9)     3.8            2.3     1.0 (−0.7 to 2.8)      10.26 (9.14 to 11.52)   −2.2 (−3.9 to −0.5)

  C16                                  Stomach                                 37.3        15.9          −4.0 (−4.5 to −3.5)     13.2           6.7     −3.8 (−4.7 to −2.9)    2.35 (2.19 to 2.51)     −0.2 (−1.1 to 0.7)

  C18--C21                             Colorectum                              21.2        13.0          −1.7 (−2.3 to −1.0)     13.2           11.6    −1.8 (−2.7 to −0.8)    1.63 (1.52 to 1.75)     0.2 (−0.9 to 1.2)

  C33--C34                             Trachea, bronchus, lung                 106.4       47.3          −3.6 (−3.9 to −3.2)     10.2           12.5    1.2 (0.6 to 1.9)       7.00 (6.59 to 7.43)     −4.8 (−5.9 to −3.6)

  C64--C68                             Urinary organs                          16.8        14.6          −1.5 (−2.1 to −1.0)     4.8            3.7     −1.5 (−2.4 to −0.7)    3.92 (3.53 to 4.34)     0.4 (−0.5 to 1.3)

  I00--I99                            Circulatory diseases                     639.1       236.9         −4.4 (−4.8 to −4.0)     212.5          65.0    −6.0 (−6.3 to −5.6)    3.19 (3.13 to 3.25)     1.6 (1.1 to 2.0)

  I10--I15                             Hypertensive diseases                   21.1        47.2          6.3 (5.0 to 7.7)        9.3            20.7    4.9 (4.1 to 5.8)       2.48 (2.35 to 2.63)     1.7 (0.5 to 2.9)

  I20--I25                             Ischaemic heart diseases                383.5       99.7          −6.2 (−6.7 to −5.8)     105.0          18.5    −8.6 (−9.2 to −8.1)    4.06 (3.95 to 4.17)     2.7 (1.9 to 3.4)

  I21--I22                              Myocardial infarction                  63.3        23.8          −4.4 (−5.4 to −3.4)     18.2           4.9     −6.9 (−8.1 to −5.8)    3.96 (3.73 to 4.21)     3.3 (2.0 to 4.6)

  I42                                  Cardiomyopathy                          55.7        19.5          −4.1 (−5.3 to −2.9)     12.6           4.3     −6.2 (−7.7 to −4.7)    4.38 (4.09 to 4.69)     2.2 (0.9 to 3.6)

  I60--I69                             Cerebrovascular diseases                136.9       30.7          −7.8 (−8.6 to −7.0)     73.5           10.6    −9.3 (−10.0 to −8.7)   2.11 (2.03 to 2.19)     1.6 (0.9 to 2.2)

  J00--J99                            Respiratory diseases                     76.8        26.3          −5.1 (−5.8 to −4.4)     17.0           6.2     −4.8 (−6.3 to −3.3)    4.94 (4.63 to 5.28)     −0.3 (−1.7 to 1.1)

  J40--J44                             COPD                                    18.6        7.2           −3.0 (−4.0 to −2.0)     2.2            1.4     −1.8 (−3.3 to −0.3)    6.56 (5.67 to 7.59)     −0.6 (−2.5 to 1.3)

  K00--K93                            Digestive diseases                       52.1        63.4          0.0 (−1.0 to 0.9)       22.3           19.1    −0.5 (−1.8 to 0.7)     2.55 (2.43 to 2.67)     0.7 (−0.3 to 1.7)

  K70, K74                             Liver cirrhosis                         22.8        43.8          1.6 (0.4 to 2.7)        14.7           15.0    0.5 (−1.1 to 2.0)      2.30 (2.18 to 2.44)     1.3 (0.1 to 2.5)

  D50--H95, L00--R94                  Other diseases                           58.8        43.6          −0.4 (−1.4 to 0.6)      43.3           18.0    −2.6 (−3.5 to −1.7)    1.92 (1.84 to 2.00)     2.3 (1.8 to 2.8)

  E10--E14                             Diabetes mellitus                       6.8         9.2           0.1 (−1.3 to 1.5)       6.2            2.6     −2.8 (−4.3 to −1.4)    1.52 (1.38 to 1.68)     4.2 (2.0 to 6.4)

  V01--Y98                            External causes                          465.3       125.1         −5.6 (−6.2 to −5.1)     86.7           26.8    −5.7 (−6.2 to −5.1)    5.21 (5.06 to 5.37)     0.0 (−0.4 to 0.3)

  V01--V99                             Transport accidents                     62.8        9.1           −7.9 (−9.1 to −6.7)     11.8           2.8     −6.2 (−7.5 to −4.9)    4.49 (4.12 to 4.88)     −1.5 (−2.8 to −0.2)

  W00--W19, W65--W74, X00--X09, X31    Falls, drowning, fire, excessive cold   112.1       28.6          −6.0 (−6.7 to −5.2)     20.4           4.1     −6.4 (−7.7 to −5.2)    5.45 (5.14 to 5.79)     0.7 (−0.2 to 1.7)

  X40--X49                             Accidental poisoning                    72.5        40.0          −1.9 (−3.0 to −0.8)     16.1           10.3    −2.9 (−3.8 to −2.1)    4.59 (4.30 to 4.89)     0.7 (−0.2 to 1.6)

  X42                                   Poisoning by narcotics\*               NA          20.4          2.3 (−3.3 to 7.9)       NA             5.3     10.9 (4.4 to 17.4)     6.88 (5.69 to 8.32)     −9.4 (−12.7 to −6.0)

  X45                                   Poisoning by alcohol                   60.5        16.8          −5.4 (−6.5 to −4.3)     14.9           3.6     −6.1 (−6.9 to −5.3)    4.07 (3.77 to 4.38)     0.7 (−0.3 to 1.6)

  X60--X84                             Suicide                                 99.2        27.9          −6.4 (−7.1 to −5.8)     19.2           3.9     −6.7 (−7.9 to −5.5)    6.15 (5.73 to 6.60)     0.3 (−0.6 to 1.1)

  X85--Y09                             Homicide                                60.1        5.3           −10.5 (−11.2 to −9.7)   7.1            1.8     −8.2 (−10.1 to −6.3)   4.78 (4.34 to 5.27)     −1.6 (−3.7 to 0.6)

  F10, G31.2, X45                      AP                                      68.8        30.5          −2.2 (−3.5 to −0.9)     16.5           5.8     −3.2 (−4.4 to −2.0)    4.09 (3.85 to 4.35)     1.3 (0.3 to 2.4)

  R96--R99                            Unknown causes                           35.0        23.5          −2.3 (−3.1 to −1.6)     4.5            5.2     −1.6 (−2.9 to −0.3)    5.80 (5.28 to 6.38)     −0.4 (−1.8 to 1.0)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*2007--2016 (only single cases before that period).

AAPC, average annual percentage change; AP, alcohol poisoning, mental disorders due to alcohol and alcohol-related degeneration of the nervous system as a group; ASMR, age-standardised mortality rate per 100 000 person-years (European standard population); CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICD, international classification of diseases; MRR, mortality rate ratio (adjusted for age (5-year age groups) and year of death); NA, not applicable; UADT, upper aerodigestive tract.

Deaths from circulatory diseases formed the largest group, accounting for 36.4% and 35.8% of the cases among men and women, respectively. Circulatory disease mortality in men was three times that in women ([table 1](#T1){ref-type="table"}, online [supplementary figure S1](#SP1){ref-type="supplementary-material"}). Female mortality declined faster than male mortality; for men, the decline accelerated from 2007 onwards (AAPC −6.0) (online [supplementary table S1](#SP1){ref-type="supplementary-material"}). Sex inequalities widened significantly over time. A particularly rapid decrease was observed in mortality from ischaemic heart disease and cerebrovascular disease ([table 1](#T1){ref-type="table"}). Substantial sex disparities in mortality from ischaemic heart disease were found in the younger age group (MRR 6.54) (online [supplementary table S2](#SP1){ref-type="supplementary-material"}).

The risk of death from neoplasms among men was nearly twice that among women; however, the decline was slightly faster for men. Extremely high MRRs were observed for UADT and lung cancer (10.26 and 7.00, respectively). While male mortality from these cancers decreased significantly, female mortality remained unchanged for UADT cancer and increased for lung cancer. Thus, sex differences have diminished significantly over time. The MRRs in the older age group were approximately twice those in the younger age group for UADT cancer (10.40 and 5.75, respectively) and for lung cancer (7.12 and 3.00, respectively).

A fivefold male disadvantage in respiratory disease mortality persisted throughout the study period. An especially high, but somewhat decreasing MRR was found for COPD; mortality decreased faster among men ([table 1](#T1){ref-type="table"}, [figure 3](#F3){ref-type="fig"}); also here, the MMR was twice as high in the older age group compared with the younger age group (6.61 vs 3.09).

![Three-year moving age-standardised mortality rates (European standard population) by selected tobacco-induced and/or alcohol-induced death causes, age 20--69 years, Estonia, 1995--2016. AP, alcohol poisoning, mental disorders due to alcohol and alcohol-related degeneration of the nervous system as a group; COPD, chronic obstructive pulmonary disease; UADT, upper aerodigestive tract.](bmjopen-2018-026210f03){#F3}

The MRR for digestive diseases remained near 2.5 with no significant change over time. The liver cirrhosis mortality curve followed the shape of the digestive disease mortality curve ([figures 2 and 3](#F2 F3){ref-type="fig"}), increasing during the first subperiod and fluctuating afterwards; mortality in men exceeded that in women more than twice (no differences between the younger and older age groups) and sex inequalities grew slightly over time ([table 1](#T1){ref-type="table"}, online [supplementary tables S1 and S2](#SP1){ref-type="supplementary-material"}).

There was a stable over fivefold higher male mortality from external causes. Mortality in both sexes dropped almost at the same pace; the decrease in men was more rapid in the later subperiod (AAPC −7.3). Poisoning by narcotics was the only cause manifesting a rapid increase with a decreasing sex gap. All selected external causes showed larger sex disparities in the younger than in the older age group; the highest MRRs were detected for suicide (6.98 in the younger and 5.59 in the older age group).

Mortality from AP fluctuated in the first subperiod and decreased rapidly from 2007 onwards for both sexes (AAPC −7.4 for men and −8.9 for women) (online [supplementary table S1](#SP1){ref-type="supplementary-material"}); however, a continuous, fourfold male disadvantage was evident ([table 1](#T1){ref-type="table"}, online [supplementary figure S1](#SP1){ref-type="supplementary-material"}); the MRR in the younger age group exceeded that in the older age group (4.63 and 3.82, respectively).

The analysed health behavioural characteristics demonstrated opposite trends ([figure 4](#F4){ref-type="fig"}). Daily smoking prevalence decreased from 47.1% among men and 21.7% among women in 1996 to 30.9% and 15.8%, respectively, in 2016, with the men-to-women PPR of 2.16 (95% CI 2.05 to 2.27). Heavy episodic drinking prevalence increased from 20.0% among men and 2.3% among women in 2000 to 27.3% and 5.2%, respectively, in 2016; the men-to-women PPR was 6.39 (95% CI 5.78 to 7.06). Hazardous drinking prevalence in men rose from 8.0% in 1996 to its maximum of 18.6% in 2008, then reversed and reached 15.6% in 2016; among women, the prevalence was 1.1% in 1996 and 2.9% in 2016. The men-to-women PPR was 5.84 (95% CI 5.19 to 6.57).

![Age-standardised prevalence proportions (European standard population) for daily smoking, heavy episodic drinking and hazardous drinking, age 20--64 years, Estonia, 1996--2016.](bmjopen-2018-026210f04){#F4}

Discussion {#s4}
==========

Premature mortality in Estonia has decreased considerably in 1995--2016. However, this positive development has not reduced the extremely large relative sex disparities as male and female mortality kept declining at the same pace. Large-scale health system reforms performed after regaining Estonian independence, including the utilisation of new medical technologies, better healthcare and a solidarity-based health insurance system, markedly contributed to the downturn in mortality.[@R5] There is no reason to believe that access to and quality of healthcare varies between men and women; likewise, methods of assigning cause of death do not differ markedly between sexes. Although there exist sex differences in utilisation of healthcare services in Estonia,[@R25] their effect on the sex gap in mortality is presumably small. Thus, in interpreting sex disparities in mortality, we should focus on behavioural risk factors. Here, we have addressed tobacco smoking and alcohol consumption as well-known strong mortality risk factors,[@R17] which contribute to the sex gap in mortality through the different prevalence among men and women.[@R28] Both exposures are potentially controllable in the population by effective public health policy. We did not consider other behavioural risk factors for mortality, for example, excess weight or physical inactivity, because their prevalence has not notably differed among men and women in Estonia.[@R15] In the low-income and middle-income countries of Europe, the population attributable risk of overweight and obesity for mortality was estimated to be approximately half of that of smoking and alcohol combined.[@R29] By a conservative estimate, based on 2003--2005 data, smoking-related and alcohol-related deaths accounted for 71% of the mortality sex gap in Estonia.[@R30] Consequently, a clear dominance of two major adverse health behaviours in Estonia leaves little space for the possibility that other health determinants can be significant contributors to this gap in premature mortality.

Tobacco {#s4a}
-------

Tobacco smoking is known to be the major avoidable risk factor for cancer, circulatory and respiratory diseases,[@R17] which are the leading groups of non-external causes of death. As smoking is the dominant cause of lung cancer, mortality from it follows the trend of smoking prevalence in the population with a lag time of some decades.[@R31] In our study, the lung cancer mortality decreased substantially in men and increased slightly in women, indicating sex dissimilarities in the trend of smoking prevalence in the past. In men, the lung cancer mortality trend was consistent with the COPD mortality trend, which is also known to reflect changes in smoking behaviour.[@R21] The COPD mortality in women fluctuated due to the small number of cases. Both, the lung cancer and COPD men-to-women MRRs pointed to a much higher smoking prevalence among men.

According to the Finbalt survey, self-reported daily smoking prevalence showed a steady decrease since 2004 for both sexes, but the prevalence in men was twice that of women; however, the smoking prevalence among men has declined faster than that among women. In Europe, men-to-women smoking PPRs above 1.5 have been mainly seen in postcommunist countries where women have traditionally smoked far less.[@R34] Premature mortality among smokers is estimated to be 2--3 times that among never smokers, which means an average of 10 years shorter life expectancy if they do not quit smoking.[@R35] If (by an optimistic scenario) smoking prevalence in Estonia keeps the current trend, a continuing decrease in premature mortality rates and narrowing of the sex gap would be expected.

Alcohol {#s4b}
-------

Another strong behavioural risk factor for mortality, alcohol consumption, is related to cancer, digestive diseases and mental disorders, and there is no safe amount of alcohol for these diseases.[@R18] Alcohol is closely linked to accidents, suicide and homicide.[@R19] Different studies have led to controversial conclusions about a potential cardioprotective effect of light to moderate alcohol drinking[@R38]; however, accumulating evidence suggests that there is no beneficial effect of alcohol intake on circulatory diseases.[@R19] Heavy drinking has been convincingly found to be detrimental to cardiovascular health.[@R27] Numerous studies have demonstrated that the high premature mortality among men in the European countries of the former Soviet Union (including Estonia) has been driven by circulatory diseases and has reflected the volume and pattern of alcohol consumption.[@R5]

Estonia is recognised as a spirits/beer-drinking country, where alcohol is consumed irregularly with binge drinking occasions on weekends and where drunkenness among men is socially acceptable.[@R22] Pure alcohol consumption per capita at age ≥15 years was 10.2 L in 2016 and it has diminished by 1.7 L since 2009. These estimates increased from 1995 and peaked at 14.8 L in 2007.[@R22]

In our study, the decline in circulatory disease mortality was significantly faster among women resulting in an increasing sex gap. Of all the main groups of circulatory diseases, elevated mortality has been found only for hypertensive disease. At the same time, an impressive decrease in cerebrovascular disease mortality was apparent. Partly explained by mutual erroneous coding,[@R49] this practice had a similar impact on male and female mortality. Harmful drinking is likely responsible for the increasing sex gap in circulatory disease mortality rather than smoking, as there has been a faster decline in smoking prevalence among men. However, we should keep in mind the effect of largely improved healthcare on the steady decline in circulatory disease mortality.

The level of liver cirrhosis mortality is often used as an indicator of the volume of drinking in the population as average volume of alcohol consumption is associated with liver cirrhosis mortality in a dose--response manner; the link is estimated to be stronger in spirits-drinking countries.[@R19] Thus, by estimation, in spirits-drinking countries, a 1 L increase in alcohol consumption per capita entails a 3.5% increase in liver cirrhosis mortality in the same year.[@R51] Premature liver cirrhosis mortality rates in Estonia grew sharply up to 2007--2008, which coincided with the highest level of per capita alcohol consumption. The men-to-women liver cirrhosis MRR indicated that men in Estonia used to drink much more than women, and this difference has increased in recent years. Although Estonia is known for high liver disease mortality,[@R20] these mortality rates could have been even somewhat higher because in the causes of death register, alcoholic liver disease has sometimes been erroneously coded as alcoholism.[@R9]

Drinking culture characterised by a large volume of alcohol use with binge drinking episodes is responsible for the elevated mortality due to alcohol poisoning in the population.[@R4] In the current study, we used a joint category of AP mortality instead of alcohol poisoning alone because of long-term death certificate coding practices (at least since 2000) in Estonia that have led to an undercoding of alcohol poisoning and overcoding of alcoholism.[@R9] AP mortality increased slightly among men up to 2007 (the peak of alcohol consumption in the population) and fluctuated without a noticeable trend among women; the following decrease was rapid, especially among women. The men-to-women MRR for AP demonstrated a more hazardous drinking pattern among men.

Because there is a strong association between alcohol consumption and mortality from external causes, these mortality rates should have mirrored alcohol-induced (liver disease and AP) mortality. However, we did not observe a similar trend during the first half of the study period. While there was an upward trend in alcohol-induced mortality in 1995--2007, mortality from external causes dropped for both sexes throughout the study period. The decline was faster since 2007 and was consistent with the reduced alcohol-induced mortality. Male disadvantage was obvious and did not decrease for any of the single external causes that could be related to alcohol. The opposite trends for external causes and for alcohol-induced causes of death up to 2007 cannot be explained by a weak effect of alcohol but was presumably the result of improved safety and major innovations in healthcare after the change in political regime that could save more lives than alcohol could kill.

Although heavy alcohol consumption is underestimated in self-reports,[@R53] the Finbalt survey data have supported the findings from the analysis of premature mortality, indicating that drinking habits of men were far more detrimental than those of women. Heavy episodic drinking and hazardous drinking prevalence among men exceeded that of women about six times. Both characteristics had an increasing prevalence trend among women; among men, while heavy episodic drinking prevalence continued to grow, hazardous drinking prevalence trend reversed in 2008, corresponding to the economic recession.

Tobacco and alcohol combined {#s4c}
----------------------------

Two major groups of causes of death---cancer and circulatory diseases---share two main behavioural risk factors: smoking and alcohol consumption. Not surprisingly, premature mortality from these causes among men was many times higher than that among women because men's smoking and drinking habits are much more detrimental. The joint effect of tobacco and alcohol can be observed in UADT cancer mortality rates as an indicator of heavy smoking in combination with heavy drinking.[@R17] The marked 10-fold male disadvantage in UADT cancer mortality reveals the essence of the extremely high male premature mortality in Estonia. A strong link of alcohol and tobacco with premature mortality was evident from a study of 169 autopsies in Estonia (male deaths, aged 25--54 years), where alcohol was found in the blood in 95% of cases and proxy informants reported current smoking among 78% of them.[@R55]

Tobacco and alcohol policy {#s4d}
--------------------------

The decreasing smoking prevalence indicates that the tobacco control policy in Estonia can be considered a success: inflation-adjusted tobacco prices have grown steadily, advertising of tobacco products is banned, smoking in public places is restricted, and smoking cessation service is a part of the healthcare system.[@R56] Because there has been no cigarette industry in Estonia since 1996 and no producers lobby to resist regulations, it has been easier to implement tobacco control programmes. However, tobacco is still readily available, with 3.9 sales points per 1000 people in 2015.[@R57]

In contrast to tobacco policy, alcohol control measures in Estonia have been weak.[@R48] Summarised by WHO, the key interventions to handle the adverse effects of alcohol include a pricing policy, restricting advertising and limiting availability. In addition, drink-driving, brief counselling and treatment for alcohol dependence should be addressed.[@R58]

The excise tax for the most consumed beverages (strong alcohol and beer) was raised by 10% and 20% (twice) in 2008, then by 10% in 2010, by 5% each year in 2012--2014, and by 15% in 2015 and 2016 (by the Excise Tax Act). The economic recession in combination with an increase in alcohol prices contributed to a marked reduction in alcohol consumption in 2008--2009.[@R48] However, subsequent growth of average income has nullified the effect of higher taxes, and alcohol prices have remained relatively low.[@R22] Thus, for example, the price of a 0.5 L vodka bottle with 40% alcohol content is equal to the price of two cups of coffee. A minimum unit price policy as a potentially successful measure in reducing heavy drinking[@R59] has not been considered in Estonia so far.

The Estonian government has made some efforts to control the availability and advertisements of alcohol: retail sale of alcohol is only permitted from 10:00 to 22:00 hours with no exceptions on weekends; the age limit for buying or consuming alcohol is 18 years; selling alcohol to persons with signs of intoxication is prohibited; and the Advertising Act regulates alcohol advertising. No limitations exist for the number of alcohol sales points---in 2016, there were 5.6 sales points per 1000 people.[@R22] Thus, changes have been minor, and alcohol still has remained extremely affordable and available in Estonia.

The only effective antialcohol measure so far has been strict control of drunk driving. The legal blood alcohol concentration is 0.02% in Estonia while driving, and random breath testing is implemented. A rapid decrease in mortality due to transport accidents attests to the benefits of these measures.

Brief screening and counselling for alcohol misuse are limited in primary healthcare because these programmes are not incorporated into the services list of the health insurance fund and, therefore, rely on project funding from the European Social Fund and the good will of family doctors. Treatment for alcohol dependence is an expensive out-of-pocket service, and only therapy for acute conditions is financed by the health insurance fund.

A short overview of alcohol-related harm and evidence-based recommendations to reduce it were published in the 'Green Paper on Alcohol Policy' issued by the Ministry of Social Affairs.[@R61] However, there are still no successful legislation initiatives to implement these guidelines. Although the seriousness of the problems associated with alcohol is admitted by the public,[@R22] the draft act on alcohol restrictions met fierce resistance from alcohol producers and was not accepted by the government. Like elsewhere, the country's efforts have faced commercial interests of the alcohol industry to block responsible legislation.[@R62]

Limitations {#s4e}
-----------

The results of this study rely on the data quality of the Estonian causes of death register. Although in international comparisons the death data were considered to be of high quality with respect to timeliness, coverage, completeness, the used ICD revision and the proportion of unknown causes,[@R64] we are aware of some systematic misclassifications[@R9] that may bias the cause-specific mortality rates. Because of undercoding of alcohol poisoning, mortality rates for the broad category of external causes were also somewhat underestimated.

We excluded deaths with unknown age at death from the analyses; half of these were from external causes. It is likely that the majority of those would have belonged to the age group of 20--69 years. This exclusion reduced the mortality rates. As we excluded relatively more male deaths, the MRRs could be slightly reduced. In addition, deaths at the age of 20--69 years with unknown cause were more common among men. If we had known these causes, other cause-specific mortality rates would have been somewhat higher, especially in men. Thus, the unknown category additionally reduced the cause-specific MRRs.

Because the latency period between an initial exposure to tobacco and alcohol, and the onset of disease can be several decades, the patterns of premature mortality due to non-external causes of death reported here, reflect past exposure situations. It is assumed that the prevalence of adverse health behaviours and their contrasts by sex were in the past in the same order of magnitude as in some last decades.

Conclusions {#s5}
===========

Even though premature adult mortality has markedly decreased over time in Estonia, there has been no success in diminishing the large sex differences in the mortality patterns, many of which were related to smoking and excessive drinking of alcohol, both more prevalent among men. The country's population needs the implementation of a comprehensive and consistent alcohol policy while maintaining and further developing antitobacco measures.
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